Mantle cell lymphoma · 17 regimens
Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibrutinib and Rituximab Variant #02 | — | R 209 656 | 28d | ~65.3 mo | — | ~7 | ~R 794 072 PFS proxy · indirect | — |
Ibrutinib and Venetoclax Variant #01 | — | R 200 392 | 28d | ~31.3 mo | — | ~78 | ~R 13 598 349 PFS proxy · indirect | 1 |
Obinutuzumab monotherapy Variant #06 | — | R 166 941 | 21d | — | — | ~7 | ~R 310 033 indirect | — |
Arsenic trioxide and Chlorambucil Variant #01 | — | R 164 286 | 42d | — | — | ~2 | ~R 196 235 indirect | — |
Temsirolimus and Rituximab Variant #01 Partial | — | R 129 524 | 28d | — | — | ~12 | ~R 233 142 indirect | — |
Lenalidomide and Rituximab (R2) Variant #08 | — | R 106 523 | 28d | — | ~8.5 mo | ~13 | ~R 141 371 PFS proxy · indirect | 1 |
BDR Variant #01 | — | R 66 028 | 21d | — | — | ~4 | ~R 264 111 indirect | — |
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
R-BL Variant #01 | — | R 33 396 | 28d | — | — | ~6 | ~R 200 374 indirect | — |
BeRT Variant #01 Partial | — | R 32 103 | 28d | — | — | ~4 | ~R 128 413 indirect | — |
Everolimus monotherapy Variant #01 | — | R 18 360 | 28d | ~6.0 mo | ~18.1 mo | ~2 | ~R 36 719 PFS proxy · indirect | 15 |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | ~30.3 mo | — | ~8 | ~R 54 096 PFS proxy · indirect | 5 |
PEP-C Variant #01 Partial | — | R 213 | — | — | — | ~1 | ~R 213 indirect | — |
RT-PEPC N/A - protocol Partial | — | — | 120d | — | — | ~2 | — | — |
Brexucabtagene autoleucel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Pirtobrutinib monotherapy Variant #01 Partial | — | — | 28d | ~14.0 mo | — | ~2 | — | 1 |
Lisocabtagene maraleucel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
17 of 17 regimens shown